Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)

Next Previous
Trial Profile

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; Tobevibart (Primary)
  • Indications Hepatitis D
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ECLIPSE 1
  • Sponsors Vir Biotechnology

Most Recent Events

  • 16 Dec 2025 According to a Vir Biotechnology media release, clinical development costs for the ongoing trials in the ECLIPSE registrational program (ECLIPSE 1, 2 and 3) will be shared, where Norgine will contribute around 25% of go-forward external costs.
  • 14 Nov 2025 Status changed from recruiting to active, no longer recruiting.
  • 03 Nov 2025 According to a Vir Biotechnology media release, the last patient in ECLIPSE 1 is expected to reach the primary endpoint (primary completion date) in the fourth quarter of 2026, with topline data expected in the first quarter of 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top